Heron Therapeutics, Inc.
HRTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.19 | 0.04 | 0.06 | 0.39 |
| FCF Yield | -10.39% | -25.69% | -54.64% | -22.96% |
| EV / EBITDA | -76.19 | -3.72 | -2.35 | -4.50 |
| Quality | ||||
| ROIC | -7.80% | -74.25% | -74.19% | -89.71% |
| Gross Margin | 73.21% | 48.75% | 49.04% | 46.70% |
| Cash Conversion Ratio | 1.66 | 0.53 | 0.81 | 0.92 |
| Growth | ||||
| Revenue 3-Year CAGR | 10.25% | 13.74% | 6.70% | -16.05% |
| Free Cash Flow Growth | 59.83% | 59.44% | 27.93% | -7.69% |
| Safety | ||||
| Net Debt / EBITDA | -30.06 | -1.45 | -0.80 | -0.32 |
| Interest Coverage | -1.91 | -28.60 | -70.60 | -90.39 |
| Efficiency | ||||
| Inventory Turnover | 0.73 | 1.55 | 1.01 | 0.95 |
| Cash Conversion Cycle | 591.02 | 390.69 | 517.99 | 503.62 |